QuantHealth Raises $45 Mn Series B to Advance AI-Powered Clinical Trial Simulations

The funding round also received support from several existing and new investors, including Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures.

The new funding brings QuantHealth's total funding to $75 million. Earlier investors in the company include global pharmaceutical company Sanofi and Accenture Ventures, the investment arm of consulting firm Accenture.

“Today, clinical development decisions are still largely made through real-world iteration, running trials, waiting for results, and adjusting at significant cost and risk. We’re fundamentally changing that model,” said Orr Inbar, CEO and co-founder of QuantHealth. “With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital.”

Founded in 2020 by Orr Inbar, QuantHealth is an Israeli HealthTech startup that uses artificial intelligence (AI) to make clinical trials faster, smarter, and more effective.

The company has built an AI-powered simulation platform that can predict how a clinical trial is likely to perform before it starts by analyzing large amounts of medical and clinical data.

This helps pharmaceutical and biotechnology companies design better clinical trials, reduce risks and costs, and improve their chances of developing successful new medicines.

Read Also- Rime Closes $2 Mn+ Seed Funding to Bring Real-Time AI Automation to Businesses